Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: 3D1015 Injection for Patients With mCRPC [Phase 1]
A Phase 1 clinical trial evaluating 3D1015 Injection in patients with metastatic castration-resistant prostate cancer is currently recruitin…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma [Phase 1]
Pfizer is conducting a Phase 1 study of mevrometostat for relapsed/refractory small cell lung cancer, metastatic castration-resistant prosta…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) [Phase 1, Phase 2]
This document outlines a two-part clinical trial (Phase 1 dose escalation/expansion followed by Phase 2) of Tulmimetostat and Luxdegalutamid…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. [Phase 3]
A Phase 3 clinical trial is evaluating how PF-06821497 (Mevrometostat) works in men with metastatic castration-resistant prostate cancer; th…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours [Phase 1]
Phase I clinical study of HLX3902 in metastatic castration-resistant prostate cancer and other advanced/metastatic solid tumors; the trial s…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes [Phase 3]
A Phase 3 clinical trial in recruiting evaluating platinum- and taxane-based chemotherapy for metastatic castration-resistant prostate cance…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Study of PF-07248144 in Advanced or Metastatic Solid Tumors [Phase 2]
Pfizer is conducting a Phase 2 study of PF-07248144 in locally advanced or metastatic ER+ HER2- breast cancer, locally advanced or metastati…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer [Phase 1, Phase 2]
This clinical trials entry reports a Phase 1/2 study evaluating SX-682 in combination with apalutamide for metastatic castration-resistant p…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial [NA]
This clinical trial is investigating cryoablation combined with stereotactic body radiation therapy for painful bone metastases in patients …
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial is investigating the combination of docetaxel chemotherapy with green tea extract and quercetin in metastat…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study [Phase 2]
Phase 2 trial (TRAMP) testing the combo of golimumab and apalutamide for metastatic castration-resistant prostate cancer is active but not c…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 3]
A Phase 3 clinical trial is evaluating Pasritamig with docetaxel versus docetaxel alone in metastatic castration-resistant prostate cancer a…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer [Phase 2]
Phase 2 trial evaluating M1774 in hard-to-treat prostate cancer is currently active but not recruiting. The study targets castration-resista…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
Phase 1 clinical trial evaluating ARN-509 (apalutamide) in combination with abiraterone acetate in participants with metastatic castration-r…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer [Phase 1]
This is a Phase 1 clinical trial evaluating Pasritamig (JNJ-78278343) in combination with other agents for metastatic prostate cancer, curre…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
Phase 1 study of the androgen receptor antagonist apalutamide in Chinese participants with metastatic castration-resistant prostate cancer; …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating sequencing abemaciclib before 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer, w…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating anti-tumor activity of (177Lu) rhPSMA-10.1 injection in prostate cancer, including metastatic castrati…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Castrate Resistant Prostate Cancer Enhertu Therapy [Phase 2]
A Phase 2 clinical trial evaluating Enhertu (trastuzumab deruxtecan) for metastatic castration-resistant prostate cancer is currently recrui…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
This clinical trial update reports on real-world experience with lutetium vipivotide tetraxetan in metastatic castration-resistant prostate …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 3]
Phase 3 study evaluating pasritamig versus placebo in late-line metastatic castration-resistant prostate cancer is currently recruiting. Spo…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
Clinical trial update indicates Gedatolisib in combination with Darolutamide is being studied in metastatic castration-resistant prostate ca…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of ruxolitinib and enzalutamide for metastatic castration-resistant prostate cancer…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: A Study of MHB048C in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
Clinical trial update for MHB048C in patients with metastatic castration-resistant prostate cancer and advanced solid tumors; Phase 1/2, cur…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
A Phase 1 study of ACE-232 for metastatic castration-resistant prostate cancer is currently recruiting.